EXPERT PERSPECTIVES IN VITILIGO

Experts in the field discuss new therapies and how they will impact the dermatologist's practice.

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

June 17, 2024

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.

Serum-Protein-Biomarkers-May-Reveal-Clues-to-Early-Immune-Activity-Upon-Ruxolitinib-Cream-Withdrawal-in-the-TRuE-V-Long-Term-Extension-Study

MORE EXPERT PERSPECTIVES IN VITILIGO

Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.

...

David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment response with long-term use of ruxolitinib cream as well as oral JAKs on the horizon for vitiligo.

...

Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

Gina Mangin discusses the importance of educating patients on the expected timeline for repigmentation when utilizing light box therapy.

...

Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

Shanna Miranti speaks to the importance of trying and failing with topical corticosteroids and topical calcineurin inhibitors prior to prescribing patients with topical ruxolitinib.

...

Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1 Reference: Disclosures: Expert Perspectives in Vitiligo is supported by InCyte. Dr. Elbuluk has served as a consultant and advisory board member for InCyte. However, the study discussed by Dr. Elbuluk […]

...

Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years....

Shanna Miranti, MPAS, PA-C: Managing the Psychosocial Impact of Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their initial diagnosis....

Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources

Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially socioeconomically disadvantaged patients who may not be aware of these resources in their community....

Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo

Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research, which included all patients diagnosed with vitiligo treated at a private hospital and a public hospital over a period of ten years, with a focus on associated psychiatric comorbidities. She summarizes the findings of rates of anxiety and depression in patients with vitiligo in terms of gender, race, and socioeconomic status....